ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrated phenotypic-genotypic characterization of antimicrobial resistance in uropathogens: implications for targeted therapy in a North Indian cohort.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are among the most common bacterial infections globally, increasingly driven by the continous emergence of multidrug-resistant (MDR) uropathogens that complicate empirical therapy. This study employed an integrated phenotypic-genotypic approach to characterize antimicrobial resistance patterns and their therapeutic implications in a high-burden North Indian cohort. A prospective study was conducted from June 2024 to November 2025, including 1140 patients with suspected UTIs. Bacterial isolates were identified from patients with significant bacteriuria using biochemical characterization and 16S rRNA gene sequencing; and antimicrobial susceptibility testing of the isolates was performed according to CLSI 2024 guidelines. Molecular detection of key resistance and virulence determinants was carried out using PCR, and genotype-phenotype concordance was evaluated. Of 1140 samples, 354 showed bacterial growth, with a predominance in females (71.5%). Gram-negative pathogens constituted 68% of the isolates, dominated by Escherichia coli (46%), followed by Klebsiella pneumoniae and Pseudomonas aeruginosa. High resistance to first-line agents, including fluoroquinolones, β-lactams, and co-trimoxazole, was observed, whereas therapeutic efficacy was largely restricted to last-resort agents such as amikacin, fosfomycin, and polymyxin B. Among Gram-positive isolates, linezolid and vancomycin were found to be effective. Molecular analysis revealed a high prevalence of resistance genes, including that of blaCTX-M (in 42.4%), blaTEM (in 39.5%), and carbapenemase gene blaOXA-48 (in 25.4%) of the isolates, indicating widespread ESBL and emerging carbapenemase-mediated resistance. Addationally, aac(6')-Ib (56.5%) and fimH (66%) were also among the most frequently detected genes. Significant genotype-phenotype concordance (p < 0.05) supports the reliability of integrated profiling. These findings highlight the pharmacological challenges posed by MDR uropathogens and underscore the need to incorporate molecular diagnostics into routine workflows to enable precision therapy and strengthen antimicrobial stewardship strategies.
Indexed as
Identifiers
42347876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.